BMRN
Live chart
What they do
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder.
For information only · Important disclosures
Grades vs sector
Momentum42nd percentile in sectorC
Percentile within its GICS sector across the S&P 1500.
Growth80th percentile in sectorB+
Percentile within its GICS sector across the S&P 1500.
Value60th percentile in sectorB-
Percentile within its GICS sector across the S&P 1500.
Profitability27th percentile in sectorD+
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.21 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
cheaper
pricier
pricier
cheaper
cheaper
Forward EPS $6.41 vs trailing $0.37 (+1634% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 5/9 · last two fiscal years
Altman Z-score 1.8 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.2B | $348.9M | $725.0M |
| 2024 | $2.9B | $426.9M | $487.4M |
| 2023 | $2.4B | $167.6M | $62.6M |
| 2022 | $2.1B | $141.6M | $54.9M |
| 2021 | $1.8B | $-64.1M | $209.0M |
| 2020 | $1.9B | $854.0M | $-28.9M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +15.4%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 0.95 | 1.20 | +26.6% |
| 2026-05-04 | 0.91 | 0.76 | -16.9% |
| 2026-02-23 | 0.56 | 0.46 | -17.9% |
| 2025-10-27 | 0.34 | 0.12 | -64.3% |
| 2025-08-04 | 1.03 | 1.44 | +39.4% |
| 2025-05-01 | 0.95 | 1.13 | +18.6% |
| 2025-02-19 | 0.74 | 0.92 | +24.6% |
| 2024-10-29 | 0.79 | 0.91 | +14.7% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $989.7M | +19.9% |
| 2026-03-31 | $766.2M | – |
| 2025-12-31 | $874.6M | – |
| 2025-09-30 | $776.1M | – |
| 2025-06-30 | $825.4M | – |
Analyst actions
PT $122
PT $87
PT $86
PT $114
PT $60
PT $90
Insider trades
$1.2M
–
–
Stats refreshed 2026-10-21 17:58:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026